论文部分内容阅读
司帕沙星（ｓｐａｒｆｌｏｘａｃｉｎ，ＳＰＬＸ）是一新喹诺酮类抗菌药物。本试验采取随机对照方法，评价了司帕沙星治疗呼吸系统感染的有效性与安全性，选用氧氟沙星为对照。两组共治疗患者８０例，每组各４０例。结果显示，司帕沙星组与氧氟沙星组有效率分别为８７．５％和８５％，细菌清除率分别为８６．１％与８６．１％，不良反应发生率分别为７．５％和１０％，以上结果统计学均无显著性差异（Ｐ＞０．０５）。司帕沙星与氧氟沙星等６种抗菌药物的体外抗菌活性比较显示，司帕沙星对革兰氏阳性菌的ＭＩＣ９０值≤０．２５ｍｇ／Ｌ，体外抗菌活性高于氧氟沙星；对大多数革兰氏阴性菌具有良好的体外抗菌活性，与氧氟沙星相似。试验表明，司帕沙星是一个高效、安全的抗菌药物，治疗呼吸系统感染疗效肯定。
Sparfloxacin (SPLX) is a new quinolone antibacterial drug. In this study, a randomized controlled trial was conducted to evaluate the effectiveness and safety of sparfloxacin in the treatment of respiratory infections. Ofloxacin was selected as a control. Two groups were treated in 80 patients, 40 cases in each group. The results showed that the sparfloxacin group and the ofloxacin group were 87.5% and 85%, the bacterial clearance rate was 86.1% and 86.1%, the incidence of adverse reactions were 7.5 % And 10% respectively. There was no significant difference in the above statistics (P> 0.05). Sparfloxacin and ofloxacin and other six kinds of antibacterial drugs in vitro antibacterial activity comparison showed sparfloxacin against Gram-positive bacteria MIC90 value ≤ 0.25mg / L, in vitro antibacterial activity was higher than ofloxacin ; For most Gram-negative bacteria have good antibacterial activity in vitro, similar to ofloxacin. Experiments show that sparfloxacin is a highly effective and safe antibacterial drug for the treatment of respiratory infections with certain effect.